Last updated: October 1, 2026
Amisulpride is a mature, low-cost antipsychotic with two distinct commercial markets. Oral amisulpride is an established generic medicine used primarily in Europe and selected international markets. Intravenous amisulpride is a newer hospital product marketed in the United States as Barhemsys for postoperative nausea and vomiting. The oral business has limited pricing power and declining branded value. The U.S. injectable business has higher commercial value because it occupies a regulated hospital niche with limited direct competition, but its revenue base remains modest and depends on formulary adoption.
What is the current market position of amisulpride?
Amisulpride is a substituted benzamide antipsychotic that selectively antagonizes dopamine D2 and D3 receptors. At lower doses, it is used in some markets for predominantly negative symptoms of schizophrenia. At higher doses, it is used for positive symptoms and broader schizophrenia treatment.
The commercial structure is divided as follows:
| Segment |
Product form |
Principal use |
Market status |
Commercial profile |
| Oral amisulpride |
Tablets and capsules |
Schizophrenia |
Mature generic market |
Low price, broad availability |
| Intravenous amisulpride |
Injection |
Prevention and treatment of postoperative nausea and vomiting |
Branded U.S. hospital product |
Higher unit value, limited volume |
| Branded European products |
Solian, Deniban and local brands |
Schizophrenia |
Mostly mature or genericized |
Reduced branded pricing power |
Sanofi developed and commercialized Solian in several markets. Patent and regulatory exclusivity for the oral product have expired in major jurisdictions, leaving manufacturers to compete largely on price, distribution, reimbursement access and supply reliability.
The injectable product is sold in the United States as Barhemsys, developed initially by Acacia Pharma and acquired by Eagle Pharmaceuticals in 2022. The product received U.S. Food and Drug Administration approval in February 2020 for postoperative nausea and vomiting in adults, including prevention and treatment settings (FDA, 2020a).
How large is the amisulpride market?
A reliable global market figure for amisulpride alone is not publicly disclosed. Commercial databases generally include amisulpride within broader antipsychotic-market estimates, while manufacturers do not consistently report oral amisulpride revenue as a separate line item.
The market is best assessed by segment:
- The oral market is geographically broad but financially commoditized.
- The U.S. intravenous market is narrower but has higher value per treated patient.
- Hospital purchasing and formulary decisions determine most of the injectable product’s near-term sales.
- The oral product’s growth is concentrated in emerging markets where schizophrenia treatment access is expanding.
Amisulpride does not have the commercial scale of newer long-acting injectable antipsychotics such as paliperidone palmitate or aripiprazole lauroxil. It competes more directly with generic risperidone, olanzapine, quetiapine, haloperidol and sulpiride in markets where it is approved.
Regional market dynamics
Europe remains the core region for oral amisulpride because of historical regulatory approvals and established clinical use. France, Italy, Spain and several Central and Eastern European markets have had long-standing exposure to Solian or generic amisulpride.
Asia, Latin America and selected Middle Eastern markets contribute additional oral volume. These markets are more price sensitive and often have fragmented generic supply. Local registration, hospital procurement and physician familiarity matter more than brand differentiation.
The United States is commercially relevant mainly for Barhemsys. Oral amisulpride is not FDA approved for schizophrenia, and the FDA has not established it as a U.S. oral antipsychotic competitor.
What is the financial trajectory for amisulpride?
The financial trajectory is bifurcated.
Oral amisulpride: volume stability with declining value
Oral amisulpride revenue has followed the typical pattern for a mature off-patent medicine:
- Branded revenue declined after patent expiry and generic entry.
- Unit demand remains supported by chronic schizophrenia treatment.
- Average selling prices have compressed.
- Manufacturer profitability depends on scale and production efficiency.
- Revenue growth is more likely to come from geographic expansion than from price increases.
Generic substitution limits the ability of manufacturers to capture premium pricing. Public financial statements from large pharmaceutical companies generally do not identify oral amisulpride revenue separately, which indicates that it is not a material product-level driver for major multinational portfolios.
For generic manufacturers, the product can remain economically useful when produced at low cost, bundled with other central nervous system medicines or supplied through government tenders. The financial profile is therefore defensive rather than growth-oriented.
Barhemsys: higher-value niche with commercialization risk
Barhemsys has a different financial profile. It is a branded hospital product with FDA approval, U.S. commercial infrastructure and patent protection around the injectable formulation and use. Its value depends on:
- Adoption by hospitals and ambulatory surgical centers.
- Inclusion in antiemetic protocols.
- Demonstrated value against rescue-treatment costs.
- Contracting with group purchasing organizations.
- Competition from ondansetron, dexamethasone, droperidol, promethazine and other antiemetics.
- The timing and scope of generic or competing injectable entry.
Eagle Pharmaceuticals reports Barhemsys within its commercial portfolio, but public disclosures have not always provided a consistently isolated long-term revenue series for the product. Barhemsys is therefore better viewed as a contributor to Eagle’s hospital-products platform than as a large standalone pharmaceutical franchise (Eagle Pharmaceuticals, 2023, 2024).
Its financial trajectory is likely to depend more on share capture than on expansion of the total antiemetic market. A product can gain formulary access while still generating moderate revenue because the underlying clinical episode is short and dosing is limited.
What FDA regulatory status does amisulpride have?
Oral amisulpride
The FDA has not approved oral amisulpride for schizophrenia or other psychiatric indications. As a result:
- There is no U.S. Orange Book-listed oral amisulpride reference product.
- U.S. generic oral amisulpride competition is not established through the standard ANDA pathway against an approved oral reference listed drug.
- U.S. prescribers do not have routine FDA-approved oral amisulpride access.
Intravenous amisulpride
The FDA approved Barhemsys in 2020. The approved indications include:
- Prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic from another pharmacologic class.
- Treatment of postoperative nausea and vomiting in patients who have received prophylaxis with an antiemetic from a different class or who have failed prophylaxis.
The product is administered intravenously in hospital or procedural settings. Its regulatory positioning differs from oral amisulpride because the FDA review addressed a specific perioperative use rather than chronic psychiatric treatment (FDA, 2020a).
What patents protect Barhemsys and injectable amisulpride?
The relevant U.S. patent estate is associated with the injectable formulation, administration and postoperative nausea and vomiting use rather than with the basic amisulpride molecule.
| IP category |
Commercial relevance |
| Composition and formulation patents |
May cover the injectable product or formulation characteristics |
| Method-of-use patents |
May cover postoperative nausea and vomiting prevention or treatment |
| Manufacturing patents |
May protect concentration, stability, preparation or sterile production processes |
| Regulatory exclusivity |
May delay approval of certain follow-on products even after patent expiry |
The FDA Orange Book should be used as the controlling source for current listed patents, expiration dates and any pediatric exclusivity. Patent listings can change through corrections, delistings, certifications and litigation.
For financial analysis, the key distinction is between oral amisulpride and Barhemsys:
- Oral amisulpride has no meaningful molecule-level exclusivity remaining in major markets.
- Barhemsys retains value from U.S. product-specific patents and regulatory positioning.
- Patent protection for a sterile injectable can create a higher entry barrier than tablets, but it does not eliminate competition from alternative antiemetics.
- Manufacturing complexity can delay generic entry even when patent risk is manageable.
When does amisulpride lose exclusivity?
Oral amisulpride has already lost core patent exclusivity in the principal European markets where it is sold. The timing varies by jurisdiction because national patent grants, supplementary protection certificates, pediatric extensions and local launch dates differed.
Barhemsys does not have a single “amisulpride expiration date.” Its effective exclusivity depends on:
- The expiration of each Orange Book-listed patent.
- Any applicable pediatric extension.
- Whether an ANDA applicant files a Paragraph IV certification.
- Whether the patent holder brings litigation within the statutory period.
- Whether a settlement restricts the generic launch date.
- Whether the generic product can satisfy injectable manufacturing and regulatory requirements.
The relevant commercial endpoint is therefore the earliest legally permitted generic launch, not simply the earliest patent expiration date.
Are there Paragraph IV challenges to Barhemsys?
Public patent-risk analysis must distinguish confirmed litigation from potential challenge activity. A Paragraph IV filing is not itself proof that a generic will launch. The applicant must obtain FDA approval, resolve or prevail in litigation, or reach a settlement.
For Barhemsys, the business risks are:
- An ANDA challenge to listed patents.
- A declaratory-judgment or patent-invalidation action.
- A competing injectable antiemetic that does not infringe the listed patents.
- Hospital substitution driven by lower-cost alternatives rather than an approved generic of Barhemsys.
Where litigation has not been publicly confirmed in the relevant reporting period, the defensible conclusion is that generic-entry risk remains a scenario rather than a documented launch event. The Orange Book and federal court records are the controlling sources for current Paragraph IV and patent-litigation status (FDA, 2024; U.S. Courts, 2024).
How strong is the amisulpride patent estate?
Oral product estate
The oral patent estate is weak from a commercial protection perspective because the active ingredient is mature and genericized. Remaining rights, if any, are unlikely to prevent broad substitution.
Barhemsys estate
The injectable estate is stronger but narrower. Its strength rests on product-specific rights and the difficulty of developing a substitutable sterile injectable. The estate is not equivalent to broad platform protection because hospitals can use alternative antiemetics without infringing amisulpride patents.
A practical assessment is:
| Factor |
Oral amisulpride |
Barhemsys |
| Molecule exclusivity |
Expired |
Expired molecule, product-specific protection remains relevant |
| Generic competition |
Extensive outside the U.S. |
Limited direct U.S. competition |
| Formulation differentiation |
Low |
Higher |
| Method-of-use protection |
Limited commercial impact |
Potentially material |
| Manufacturing barrier |
Low to moderate |
Moderate to high |
| Pricing power |
Low |
Moderate, constrained by hospital contracting |
| Long-term growth potential |
Low |
Moderate but niche |
Which companies compete with amisulpride?
The competitive landscape differs by indication.
Oral schizophrenia market
Amisulpride competes with:
- Generic risperidone
- Generic olanzapine
- Generic quetiapine
- Generic aripiprazole
- Haloperidol
- Sulpiride
- Long-acting injectable antipsychotics
- Branded therapies with differentiated delivery systems
Long-acting injectables are commercially stronger in many markets because they address adherence and persistence. Amisulpride remains relevant where clinicians value its established efficacy profile, tolerability characteristics or local treatment guidelines.
Postoperative nausea and vomiting market
Barhemsys competes with:
- Ondansetron
- Dexamethasone
- Droperidol
- Palonosetron
- Promethazine
- Scopolamine
- Aprepitant and related neurokinin-1 antagonists
- Combination prophylaxis regimens
The principal commercial barrier is not another amisulpride product. It is the availability of inexpensive, familiar alternatives that hospitals already stock.
What licensing deals affect amisulpride?
The most important transaction in the modern U.S. amisulpride market was Eagle Pharmaceuticals’ acquisition of Acacia Pharma, which brought Barhemsys and Byfavo into Eagle’s portfolio (Eagle Pharmaceuticals, 2022).
The transaction changed the ownership and commercialization structure of the injectable product. It did not materially change the economics of generic oral amisulpride, which remains fragmented across regional manufacturers and distributors.
Historical commercialization arrangements for Solian and local amisulpride brands have varied by country. They are less important to current global valuation than the ownership and U.S. commercialization of Barhemsys.
What generic launch risks exist for amisulpride?
Oral generic launch risk
Oral amisulpride is already exposed to generic competition. The main risks are price erosion, tender losses, supply interruptions and reimbursement substitution. New entrants can increase volume but usually reduce average selling price.
Barhemsys generic launch risk
Potential U.S. generic entry would likely produce a sharp price decline if the entrant obtained broad hospital coverage. The timing could be affected by:
- Orange Book patent certifications.
- Patent litigation.
- Settlement terms.
- FDA review of the ANDA.
- Availability of sterile manufacturing capacity.
- Hospital purchasing contracts.
- Whether the entrant offers a vial, concentration and administration profile that is operationally interchangeable.
A non-infringing alternative may create commercial pressure before a direct generic launches. Hospital pharmacy committees can switch protocols based on acquisition cost, availability and clinical outcomes.
What is the outlook for amisulpride revenue?
The base case is a two-speed trajectory:
| Period |
Oral amisulpride |
Barhemsys |
| Near term |
Stable to declining value; volume supported by chronic use |
Modest growth possible through hospital adoption |
| Medium term |
Continued price pressure and regional consolidation |
Revenue sensitive to formulary penetration and competitor entry |
| Long term |
Mature generic cash flow |
Patent and market-access erosion risk |
| Upside case |
Expansion in underpenetrated markets |
Wider perioperative adoption and stronger hospital contracts |
| Downside case |
Tender losses and supply competition |
Generic or alternative-product substitution |
The global amisulpride franchise is unlikely to produce high-growth pharmaceutical economics. Its financial value lies in dependable generic demand and the more defensible, but relatively small, U.S. injectable niche.
Key Takeaways
- Oral amisulpride is a mature generic antipsychotic with low pricing power.
- Europe and selected international markets remain the principal oral markets.
- The FDA has not approved oral amisulpride for schizophrenia.
- Barhemsys is the FDA-approved intravenous amisulpride product for postoperative nausea and vomiting.
- Eagle Pharmaceuticals owns and commercializes Barhemsys following its acquisition of Acacia Pharma.
- Oral amisulpride has limited remaining exclusivity value.
- Barhemsys has greater product-specific patent and manufacturing protection, but it competes with inexpensive antiemetics.
- Public companies generally do not disclose standalone global oral amisulpride revenue.
- The financial outlook is stable-to-declining for oral amisulpride and modest-growth-to-at-risk for Barhemsys.
- The principal downside event is direct generic entry or hospital substitution by lower-cost antiemetic alternatives.
FAQs
Is amisulpride approved in the United States?
Only intravenous amisulpride, marketed as Barhemsys, is FDA approved. Oral amisulpride is not FDA approved for schizophrenia.
Is Barhemsys the same drug as Solian?
Both contain amisulpride, but they are different products with different formulations, routes of administration and approved uses. Solian is an oral psychiatric product marketed outside the United States. Barhemsys is an intravenous U.S. hospital product.
Does amisulpride have biosimilar risk?
No. Amisulpride is a small-molecule drug, not a biologic. The relevant competitive threat is generic substitution, not biosimilar competition.
Can a generic manufacturer launch oral amisulpride in the United States?
A conventional ANDA pathway requires an FDA-approved oral reference product. Because oral amisulpride lacks FDA approval, a U.S. launch would require a different regulatory strategy or a future reference-product approval.
What is the main investment risk for Barhemsys?
The main risk is commercial substitution. Hospitals can use established, lower-cost antiemetics even without a direct generic version of Barhemsys. Patent expiry or successful Paragraph IV litigation would increase that pressure.
References
Acacia Pharma plc. (2022). Eagle Pharmaceuticals completes acquisition of Acacia Pharma. Company announcement.
Eagle Pharmaceuticals, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
Eagle Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
Eagle Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (2020a). FDA approves amisulpride injection for prevention and treatment of postoperative nausea and vomiting. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Courts. (2024). PACER case locator and federal court records. Administrative Office of the United States Courts.
